{"title":"Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.","authors":"Naoto Tomita, Koichi Kitazume, Toshiki Kitajima, Hiroki Hayata, Shuku Sato, Naoya Nakamura","doi":"10.3960/jslrt.25013","DOIUrl":null,"url":null,"abstract":"<p><p>Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of diseases with a tendency to relapse and poor prognosis, especially in relapsed or refractory cases. The prognosis of patients who are not eligible for autologous hematopoietic stem cell transplantation, such as older adults and those who do not respond to chemotherapy, is extremely poor. In the phase I/II study of pralatrexate in Japanese patients with relapsed or refractory PTCL, the objective response rate was 45%, the median PFS was 150 days, and long-term remission or disease maintenance was possible in approximately 20% of the patients. However, the characteristics of patients who respond to pralatrexate are unknown. Against this background, we investigated common patient characteristics in patients who achieved long-term responses to pralatrexate. Five patients were included and their characteristics were evaluated. The disease types were PTCL-not otherwise specified (NOS) in four cases and angioimmunoblastic T-cell lymphoma (AITL) in one case. The median duration of treatment with pralatrexate was 18 months (range: 7-36 months), of which 3 patients are still being treated. There were no pathological or immunohistochemical findings common to cases that responded to pralatrexate, however, of the four PTCL-NOS patients, two were GATA3 positive. Although there are limitations due to the number of cases, considering that the response rate of pralatrexate for PTCL-NOS in existing studies was 32%, these results may lead to future advances in PTCL treatment.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 2","pages":"101-106"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical and experimental hematopathology : JCEH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3960/jslrt.25013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of diseases with a tendency to relapse and poor prognosis, especially in relapsed or refractory cases. The prognosis of patients who are not eligible for autologous hematopoietic stem cell transplantation, such as older adults and those who do not respond to chemotherapy, is extremely poor. In the phase I/II study of pralatrexate in Japanese patients with relapsed or refractory PTCL, the objective response rate was 45%, the median PFS was 150 days, and long-term remission or disease maintenance was possible in approximately 20% of the patients. However, the characteristics of patients who respond to pralatrexate are unknown. Against this background, we investigated common patient characteristics in patients who achieved long-term responses to pralatrexate. Five patients were included and their characteristics were evaluated. The disease types were PTCL-not otherwise specified (NOS) in four cases and angioimmunoblastic T-cell lymphoma (AITL) in one case. The median duration of treatment with pralatrexate was 18 months (range: 7-36 months), of which 3 patients are still being treated. There were no pathological or immunohistochemical findings common to cases that responded to pralatrexate, however, of the four PTCL-NOS patients, two were GATA3 positive. Although there are limitations due to the number of cases, considering that the response rate of pralatrexate for PTCL-NOS in existing studies was 32%, these results may lead to future advances in PTCL treatment.
外周t细胞淋巴瘤(PTCL)是一种异质性的疾病,具有复发倾向和预后差,特别是复发或难治性病例。不适合自体造血干细胞移植的患者,如老年人和化疗无反应的患者,预后极差。在日本复发或难治性PTCL患者的I/II期研究中,普拉蝶呤的客观缓解率为45%,中位PFS为150天,大约20%的患者可能长期缓解或维持疾病。然而,对praatresate有反应的患者的特征尚不清楚。在此背景下,我们调查了对准寰蝶呤有长期反应的患者的共同特征。纳入5例患者并对其特征进行评估。4例为ptcl - non - specific (NOS), 1例为血管免疫母细胞t细胞淋巴瘤(AITL)。普拉蝶呤治疗的中位持续时间为18个月(范围:7-36个月),其中3例患者仍在治疗中。对普拉蝶呤有反应的病例没有常见的病理或免疫组织化学发现,然而,在4例PTCL-NOS患者中,2例为GATA3阳性。虽然由于病例数量的限制,存在一定的局限性,但考虑到现有研究中普拉蝶呤治疗PTCL- nos的有效率为32%,这些结果可能会导致PTCL治疗的未来进展。